Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02615054 · ClinicalTrials.gov registry record
Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 58
- Enrollment target
NCT02615054: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02615054 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02615054 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 58 participants
- Enrollment target
Study Summary
This is for participants with a history of HER2-positive breast cancer and were treated with chemotherapy that increases the risk of abnormal heart function. Strain (a marker of heart function) is a new method of monitoring heart function in cancer patients and is measured with an ultrasound. Exercise testing is another method that can be used to monitor for abnormal heart function in cancer patients. The purpose of this study is to see if strain and exercise testing can be used to detect for late signs of heart damage from chemotherapy.
Interventions
- DEVICE 2D Echocardiogram
- DEVICE Cardiopulmonary exercise testing and post-CPET cardiac function
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2015-11-18 |
| Est. Completion | 2024-03-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02615054
The ClinicalTrials.gov registry entry for NCT02615054 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 2D Echocardiogram is the first listed.
NCT02615054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02615054 about?
NCT02615054 is a clinical study titled "Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors". This is for participants with a history of HER2-positive breast cancer and were treated with chemotherapy that increases the risk of abnormal heart function. Strain (a marker of heart function) is a new method of monitoring heart function in cancer patients and is measured with an ultrasound. Exerci...
What is the current status of trial NCT02615054?
This trial is currently completed. The enrollment target is 58 participants. The study started on 2015-11-18. Estimated completion is 2024-03-05.
What interventions are being tested in trial NCT02615054?
The interventions under investigation include: 2D Echocardiogram (DEVICE), Cardiopulmonary exercise testing and post-CPET cardiac function (DEVICE).
Who is sponsoring clinical trial NCT02615054?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.